Nucleic Acid Probes

Name
Nucleic Acid Probes
Accession Number
DBCAT001716
Description

Nucleic acid which complements a specific mRNA or DNA molecule, or fragment thereof; used for hybridization studies in order to identify microorganisms and for genetic studies.

Drugs
DrugDrug Description
MipomersenAn oligonucleotide drug used for the treatment of homozygous familial hypercholesterolemia.
BevasiranibInvestigated for use/treatment in macular degeneration and diabetic retinopathy.
FomivirsenIndicated for the local treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS), when other therapy has been ineffective or is considered unsuitable [FDA Label, L1428].
PatisiranA transthyretin-directed small interfering RNA used to treat polyneuropathy of hereditary transthyretin-mediated amyloidosis.
OblimersenNot Annotated
InotersenAn antisense oligonucleotide used to treat polyneuropathy of hereditary transthyretin-mediated amyloidosis.
InclisiranA PCSK9-targeting short interfering RNA (siRNA) that lowers plasma LDL-cholesterol levels.
RevusiranRevusiran is under investigation in clinical trial NCT02319005 (ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)).
GolodirsenA drug used to treat certain mutations that cause Duchenne muscular dystrophy (DMD).
Drugs & Drug Targets
DrugTargetType
MipomersenmRNA of ApoB-100target
BevasiranibVascular endothelial growth factor Atarget
Fomivirsen30 kDa immediate-early protein 2target
Fomivirsen45 kDa immediate-early protein 2target
PatisiranTransthyretin mRNAtarget
PatisiranSerum albumincarrier
Patisiranalpha1-acid glycoproteincarrier
InotersenTransthyretin mRNAtarget
InclisiranProprotein convertase subtilisin/kexin type 9target
RevusiranTransthyretintarget
GolodirsenDystrophintarget